Do you typically use NOACs or Lovenox in patients with stroke due to hypercoagulability from malignancy?

We can extrapolate from studies of venous thromboembolism associated with cancer. Apixaban (at VTE treatment dose) has been compared to dalteparin in an open-label RCT in the CARAVAGGIO trial and edoxaban was compared to dalteparin in an open-label RCT in the Hokusai VTE Cancer trial. Both painters showed that apixaban and edoxaban were non-inferior compared to low molecular weight heparin in the prevention of recurrent thrombosis. Apixaban had no major bleeding risk compared to dalteparin (edox...